Genpact Ltd Files Definitive Proxy Statement
Ticker: G · Form: DEFA14A · Filed: Apr 10, 2024 · CIK: 1398659
| Field | Detail |
|---|---|
| Company | Genpact LTD (G) |
| Form Type | DEFA14A |
| Filed Date | Apr 10, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, sec-filing, governance
Related Tickers: G
TL;DR
Genpact filed its proxy statement, get ready to vote.
AI Summary
Genpact Limited filed a Definitive Proxy Statement (DEFA14A) on April 10, 2024. This filing is a standard proxy statement used to solicit votes from shareholders for an upcoming meeting. It does not contain specific proposals or financial details beyond its classification as a proxy statement.
Why It Matters
This filing is a procedural step for Genpact Limited to communicate with its shareholders regarding voting matters, which is essential for corporate governance.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEFA14A) and does not contain new material information that would typically impact stock price.
Key Players & Entities
- Genpact Limited (company) — Registrant
- 0001140361-24-019061 (filing_id) — Accession Number
- April 10, 2024 (date) — Filing Date
FAQ
What type of SEC filing is this?
This is a DEFA14A, a Definitive Proxy Statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934.
Who is the registrant for this filing?
The registrant is Genpact Limited.
When was this filing submitted?
This filing was submitted on April 10, 2024.
What is the purpose of a DEFA14A filing?
A DEFA14A is used to solicit votes from shareholders for an upcoming meeting and is filed after any preliminary proxy materials.
Does this filing contain specific proposals or financial details?
The provided text is a header and does not detail specific proposals or financial information; it confirms the filing type and registrant.
Filing Stats: 495 words · 2 min read · ~2 pages · Grade level 17.2 · Accepted 2024-04-10 15:04:13
Filing Documents
- ny20026590x1_defa14a.htm (DEFA14A) — 24KB
- 0001140361-24-019061.txt ( ) — 25KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 GENPACT LIMITED (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. Genpact Limited Canon's Court 22 Victoria Street Hamilton HM 12 Bermuda SUPPLEMENT TO THE PROXY STATEMENT FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 2, 2024 This Proxy Statement Supplement ("Supplement") is being filed on April 10, 2024 to supplement and clarify information contained in the Definitive Proxy Statement filed by Genpact Limited ("Genpact" or the "Company") with the U.S. Securities and Exchange Commission (the "SEC") on March 20, 2024 (the "Proxy Statement") and made available to the Company's shareholders in connection with the solicitation of proxies on behalf of the Board of Directors of the Company for its 2024 Annual General Meeting of Shareholders (the "Annual Meeting"), to be held on May 2, 2024 at 12:00 PM (local time), at 5 Merchant Square, 5 th Floor, London, W2 1AY United Kingdom. The Company urges you to read the Proxy Statement and this Supplement in their entirety. Except as specifically supplemented by the information contained in this Supplement, all information set forth in the Proxy Statement remains unchanged. Institutional Shareholder Services ("ISS"), a proxy advisory firm, has recommended that Genpact shareholders vote against Proposal No. 2 in the Proxy Statement, which is a non-binding, advisory vote to approve the compensation of the Company's named executive officers (the "Say-on-Pay proposal"). According to its 2024 Proxy Analysis& Benchmark Policy Voting RecommendationsReport, ISS is recommending against the Say-on-Pay proposal because the Company accelerated the vesting by one year of equity awards held by Kathryn Stein, a former executive officer and one of its named executive officers for 2023, upon a termination of employment that was not clearly involuntary. This Supplement is being filed with the SEC and made available to shareholders to clarify that Ms. Stein's separation from the Company was an involuntary termination by the Company without cause and the Company's acceleration of the vesting of her equity awards by a year was provided in accordance with the terms of her employment agreement for an involuntary termination without cause. The Board of Directors of Genpact recommends that you vote " FOR " the approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the SEC's compensation disclosure rules.